1 A frank dialogue on the future of HIV treatment All the way from the factory to the patient Sunday 20 th July 2014, 13:30 – 15:30 Presented at the 20 th International AIDS Conference in Melbourne, Australia

In memoriam to our friend and mentor, Joep Lange Executive Scientific Director of the Amsterdam Institute for Global Health and Development (AIGHD), Professor of Medicine, Head of the Department of Global Health, University of Amsterdam, Executive Scientific Director of the Amsterdam Institute for Global Health and Development (AIGHD) Joep has been involved in HIV research and treatment since He has been the architect and principal investigator of several pivotal trials on antiretroviral therapy and on the prevention of mother-to-child transmission of HIV in both the developed and developing world. He was Chief of Clinical Research and Drug Development at the Global Programme on AIDS of the World Health Organization in Geneva from 1992 to From 2002–2004 he was President of the International AIDS Society. He has served on numerous advisory boards including the Strategic and Technical Advisory Committee of the WHO HIV Department, the External Advisory Committee of the US HIV Vaccine Trials Network and the International Advisory Board of the Institute for Global Health of Imperial College, and as the Chairman of the PharmAccess Foundation (which he founded) and as Scientific Advisor to the Board of the Health Insurance Fund Foundation, which pioneers mechanisms of sustainable financing of health care in resource-poor settings. Joep Lange founded and was Editor-in-Chief of the Journal Antiviral Therapy and has served on several other editorial boards of scientific journals. He has published more than 350 papers in peer- reviewed journals n 2007 he was awarded the Eijkman medal for his achievements in Tropical Medicine and International Health.

3 ‘0‘0 A frank dialogue on the future of HIV treatment All the way from the factory to the patient 13:30 13:35 14:00 14:25 14:55 15:25 Welcome and introduction Joep Lange Amsterdam Institute for Global Health and Development, The Netherlands Evidence and policy gaps on ART at 500 CD4, TasP and PrEP Pedro Cahn Fundacion Huesped, Argentina Fabio Mesquita MoH, Brazil Next generation ARVs and dose optimization David Ripin CHAI, United States Velephi Okello MoH, Swaziland Summary and close See inside a Manufacturer Anil Soni Mylan Inc., United States Gregg Alton Gilead Sciences, United States Sustainable financing of ART Sergio Bautista National Institute of Public Health, Mexico Velephi Okello MoH, Swaziland

4 House Keeping Please switch them off now Feedback Please fill in the evaluation forms and hand them to the staff at the exit Mobile Phones Please use the questions cards Or make use of the microphones on stands Please use the questions cards Or make use of the microphones on stands Questions & Comments Continues Professional Development This session is credited with 1 CPD point by the Australasian Society for HIV Medicine Please sign the attendance list at the end of the session in order to receive the credit point This session is credited with 1 CPD point by the Australasian Society for HIV Medicine Please sign the attendance list at the end of the session in order to receive the credit point

5 This meeting is organised and supported by MYLAN Laboratories Ltd. India The views expressed in the slides are those of the individual faculty members and do not necessarily reflect the views of MYLAN Laboratories Ltd. India. The presentations may include discussions on off-label use of drugs. Disclaimer

6 A frank dialogue on the future of HIV treatment All the way from the factory to the patient Sunday 20 th July 2014, 13:30 – 15:30 Presented at the 20 th International AIDS Conference in Melbourne, Australia